Loading...
XSHE
300871
Market cap556mUSD
Dec 05, Last price  
19.53CNY
1D
1.14%
1Q
-12.62%
IPO
-62.68%
Name

Wuhan Hvsen Biotechnology Co Ltd

Chart & Performance

D1W1MN
XSHE:300871 chart
P/E
P/S
3.28
EPS
Div Yield, %
1.38%
Shrs. gr., 5y
0.02%
Rev. gr., 5y
22.95%
Revenues
1.20b
+17.71%
257,783,400399,715,931421,874,231427,217,126777,458,548996,216,8171,022,900,7921,019,758,7981,200,327,933
Net income
-20m
L
49,423,10088,424,28471,401,57368,766,353150,156,108132,865,53452,706,47516,780,818-20,155,591
CFO
44m
-53.15%
60,004,00080,558,56221,095,638105,241,48248,349,261155,718,48996,680,49092,919,34343,531,846
Dividend
May 29, 20240.27 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hvsen Biotechnology Co., Ltd. engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. Its products include tylvalosin raw materials, various tylvalosin preparations, florfenicol preparations, and other macrolides products. The company produces various veterinary drug products of raw materials and preparations, as well as traditional Chinese medicines extractives. Hvsen Biotechnology Co., Ltd. is based in Wuhan, China.
IPO date
Aug 24, 2020
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT